Approach to the patient with APS-1/APECED
The Journal of Clinical Endocrinology & Metabolism · 16.10.2026 · 111 (11) · 3277-3285
DOI: 10.1210/clinem/dgag282 ↗Kurz gefasst
Fallbericht in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, online erschienen am 16.07.2026. Verfasst von Taura Webb und 2 weiteren Autor:innen. Beteiligte Einrichtung: Fungal Pathogenesis Section, Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases (NIAID), Natio…. Hauptthemen laut MEDLINE: Polyendocrinopathies, Autoimmune. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Institute of Allergy and Infectious Diseases, U.S. Department of Health and Human Services, Intramural Research Program.
Abstract (Originalsprache)
Autoimmune polyendocrine syndrome type 1 (APS-1), also known as autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED), is a monogenic disorder of impaired central immune tolerance classically inherited in an autosomal recessive manner and caused by biallelic deleterious variants in the autoimmune regulator (AIRE) gene, leading to chronic mucocutaneous candidiasis and multiorgan autoimmunity. Although hypoparathyroidism and adrenal insufficiency are among the most common and clinically consequential manifestations, it is increasingly recognized that several non-endocrine features—including autoimmune enteritis, urticarial eruption (termed APECED rash), enamel hypoplasia, autoimmune pneumonitis, and autoimmune hepatitis—often precede classical endocrinopathies, contributing to delayed diagnosis. Endocrinologists are often among the first specialists to encounter these patients and play a central role in early recognition and longitudinal care. Here, we present 5 cases that illustrate the expanding clinical spectrum of APS-1, novel genetic mechanisms, key diagnostic challenges, and emerging therapeutic approaches. These cases highlight the importance of applying expanded clinical criteria and recognizing the limitations of standard genetic testing, including the need to consider deep intronic and dominant-negative AIRE variants. Finally, evolving mechanistic insights have established APS-1 as an interferon-γ-driven disease, providing a rationale for emerging targeted immunomodulatory therapies such as Janus kinase inhibition with ruxolitinib. Early diagnosis enables proactive surveillance and may allow timely initiation of disease-modifying treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Fungal Pathogenesis Section, Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD 20892, USA.
ORCID-Profile: Michail S Lionakis
Förderung
- National Institute of Allergy and Infectious Diseases
- U.S. Department of Health and Human Services
- Intramural Research Program
- United States Government
- NIAID NIH HHS
- NIH HHS
- NIH
- National Institutes of Health
Zitieren
APA
Webb, T., Pechacek, J., & Lionakis, M. S. (2026). Approach to the patient with APS-1/APECED. The Journal of Clinical Endocrinology & Metabolism, 111(11), 3277-3285. https://doi.org/10.1210/clinem/dgag282
Vancouver
Webb T, Pechacek J, Lionakis MS. Approach to the patient with APS-1/APECED. The Journal of Clinical Endocrinology & Metabolism. 2026;111(11):3277-3285. doi:10.1210/clinem/dgag282
BibTeX
@article{Webb2026,
author = {Webb, Taura and Pechacek, Joseph and Lionakis, Michail S},
title = {Approach to the patient with APS-1/APECED},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2026},
volume = {111},
number = {11},
pages = {3277--3285},
doi = {10.1210/clinem/dgag282}
}
EUVIMED